Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced the introduction of a new education campaign designed to help answer parents' questions about immunization and to offer health-care professionals a reference tool to supplement their discussions about vaccination with patients. The site contains useful ...

November 02, 2011, Seoul, S. Korea One of the most common and serious infectious diseases, Hepatitis B, is to be targeted in a new collaborative venture between the internationally-renowned translational research institute, Institut Pasteur Korea (IP-K), and the Korean arm of the leading global healthcare company, Sanofi-Aventis Korea. The ...

(Institut Pasteur Korea) One of the most common and serious infectious diseases, hepatitis B, is to be targeted in a new collaborative venture between the internationally-renowned translational research institute, Institut Pasteur Korea, and the Korean arm of the leading global health-care company, Sanofi-Aventis Korea. The goal is to develop and ...

Merck (NYSE: MRK) (known outside the United States and Canada as MSD) and Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN, NYSE: SNY), announced today the initiation of a Phase III clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine1...

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to ...

Swiftwater, PA April 22, 2011 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, Y and ...

(Cooney Waters Group, Inc.) Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the US Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include ...

Merck and Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the initiation of a Phase III clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI). Sanofi Pasteur and the IVI will aim to raise awareness and to work to move dengue vaccination higher on the global ...

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk ...

SWIFTWATER, Pa., Oct. 25 /- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY ), announced today the results of the Phase III clinical trial of its investigational Fluzone® Intradermal (Influenza Virus Vaccine) candidate compared to Fluzone (Influenza Virus Vaccine) administered via the ...

SWIFTWATER, Pa., Oct. 8 /- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY ), has been awarded a three-year contract for $56.94 million by the U.S. Department of Health and Human Services (HHS) to maintain flocks to enable manufacturing pandemic influenza vaccine ...